Many Americans have expressed strong reservations about vaccines in general and a COVID-19 vaccine in particular, and remain unsure about whether to be vaccinated against the coronavirus (SARS-CoV-2). In this episode, guest host Claire Wulf Winiarek speaks with Janet McUlsky, convener of the COVID-19 Vaccine Education and Equity Project, and Susan Winckler, a former Chief of Staff to the FDA Commissioner and current CEO of the Reagan-Udall Foundation for the FDA, about these concerns and the potential messages and messengers that may help improve understanding.
To learn more about the important work underway by the COVID-19 Vaccine Education and Equity Project, or to join the initiative, visit covidvaccineproject.org. Findings from the COVID-19 Vaccine Confidence Project, led by the Reagan-Udall Foundation for the FDA, are at covid19.reaganudall.org.
A Historic Effort and Collaboration. Susan discusses that the vaccine was able to move along quickly due to significant collaboration and large numbers of people who were eligible for clinical trials. To ensure the vaccine could be distributed as soon as possible, manufacturers continued working on it at risk while they were under regulatory review so it could be distributed as soon as it was authorized. FDA staff members reviewed regulatory packages of the vaccine to move authorization along as quickly as possible. Janet shares that the thorough oversight and monitoring by the FDA, researchers, and physicians helped ensure the safety and effectiveness of the vaccine even though the process was much quicker. Previous pandemics and other infectious threats in the last decade also resulted in more research that allowed manufacturers to advance the vaccine more quickly in the COVID-19 pandemic.
What is The Pharmacy Benefit?
JC Scott, President & CEO of the Pharmaceutical Care Management Association, discusses the latest trends, public policy developments, and political challenges impacting drug pricing and healthcare.
You'll hear the nation's top thought leaders, policy experts, and political analysts on topics like how employers, unions, and others use Pharmacy Benefit Managers (PBMs) to drive value for their members in the face of growing healthcare costs. You'll also learn about advancements in gene therapy, biologics, other cutting edge therapies, and the patient benefits and cost challenges that come with them.
The Pharmacy Benefit will also analyze the latest news from inside the industry and give you an educated perspective on where things currently stand and where we think they're headed.